WEST PHARMACEUTICAL SERVICES, INC. (WST) FY2026 Q2 Statement of Cash Flows

Income StatementCash FlowBalance Sheet

Statement of Cash Flows

2026-04-01 to 2026-06-30

Swipe to see the full flow
WEST PHARMACEUTICAL SERVICES, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026One connected Sankey reconciles operating, investing and financing net cash flows through a shared cash pool, from beginning cash to ending cash. Ribbons flow left to right on one dollar scale. Activity totals are dark gray; beginning and ending cash are blue. Cash basis for beginning and ending balances and net cash change: Cash, cash equivalents, and restricted cash. Intermediate calculation bars are lighter gray. Net income is green for profit and red for loss. Identified asset purchases, sales and maturities are blue in either cash direction. Purple identifies capital transactions such as borrowing, repayments, share issuance and dividends. Free cash flow is a separate comparison, not an added cash flow. Read chart description and values below for full signed amounts, including zero items.Net income → Net cash from operating activities: $124,000,000.00Net income → Operating adjustments reconciliation: $30,000,000.00Depreciation → Operating adjustments reconciliation: $45,700,000.00Stock-based compensation → Operating adjustments reconciliation: $10,900,000.00Asset impairments → Operating adjustments reconciliation: $3,900,000.00Non-cash restructuring charges → Operating adjustments reconciliation: $1,000,000.00Amortization → Operating adjustments reconciliation: $500,000.00Operating adjustments reconciliation → Changes in assets and liabilities: $86,000,000.00Operating adjustments reconciliation → Other non-cash items, net: $6,000,000.00Net cash used in investing activities → investing reconciliation: $43,200,000.00investing reconciliation → Capital expenditures: $43,200,000.00Net cash used in financing activities → financing reconciliation: $164,800,000.00Borrowings under revolving credit agreements → financing reconciliation: $50,000,000.00Proceeds from stock-based compensation awards → financing reconciliation: $6,900,000.00Employee stock purchase plan contributions → financing reconciliation: $1,900,000.00financing reconciliation → Shares purchased under share repurchase programs: $156,700,000.00financing reconciliation → Repayments under revolving credit agreements: $50,000,000.00financing reconciliation → Dividend payments: $15,700,000.00financing reconciliation → Excise tax payments: $800,000.00financing reconciliation → Principal repayments on finance leases: $400,000.00Beginning cash: Cash, cash equivalents, and restricted cash → Cash sources and uses: $521,400,000.00Net cash from operating activities → Cash sources and uses: $124,000,000.00Cash sources and uses → Exchange-rate effect: $1,600,000.00Cash sources and uses → Ending cash: Cash, cash equivalents, and restricted cash: $435,800,000.00Cash sources and uses → Net cash used in investing activities: $43,200,000.00Cash sources and uses → Net cash used in financing activities: $164,800,000.00Net income: $154,000,000.00Net income+$154.00 MDepreciation: $45,700,000.00Depreciation expense+$45.70 MAmortization: $500,000.00Amortization expense+$500.00 KStock-based compensation: $10,900,000.00Stock-based compensation+$10.90 MAsset impairments: $3,900,000.00Asset impairments+$3.90 MNon-cash restructuring charges: $1,000,000.00Non-cash restructuring charges+$1.00 MOther non-cash items, net: -$6,000,000.00Other non-cash items−$6.00 MChanges in assets and liabilities: -$86,000,000.00Operating capital changes−$86.00 MNet cash from operating activities: $124,000,000.00Operating cash+$124.00 MOperating adjustments reconciliation: $92,000,000.00Borrowings under revolving credit agreements: $50,000,000.00Long-term credit line borrowings+$50.00 MRepayments under revolving credit agreements: -$50,000,000.00Long-term credit line repayments−$50.00 MPrincipal repayments on finance leases: -$400,000.00Finance lease payments−$400.00 KExcise tax payments: -$800,000.00Excise tax payments−$800.00 KDividend payments: -$15,700,000.00Common dividends paid−$15.70 MProceeds from stock-based compensation awards: $6,900,000.00Stock option exercises+$6.90 MEmployee stock purchase plan contributions: $1,900,000.00Employee stock plan proceeds+$1.90 MShares purchased under share repurchase programs: -$156,700,000.00Common stock repurchases−$156.70 MShares repurchased for employee tax withholdings: $0.00Net cash used in financing activities: -$164,800,000.00. Cash required to fund net payments.Financing cash−$164.80 Mfinancing reconciliation: $223,600,000.00Capital expenditures: -$43,200,000.00PP&E purchases−$43.20 MNet cash used in investing activities: -$43,200,000.00. Cash required to fund net payments.Investing cash−$43.20 Minvesting reconciliation: $43,200,000.00Cash sources and uses: $645,400,000.00Beginning cash: Cash, cash equivalents, and restricted cash: $521,400,000.00Beginning cash$521.40 MEnding cash: Cash, cash equivalents, and restricted cash: $435,800,000.00Ending cash$435.80 MExchange-rate effect: -$1,600,000.00FX effect−$1.60 MCASH RECONCILIATIONOperatingflowsInvestingflowsFinancingflowsFree cash flow$80.80 MOperating cash − cash spent on PP&ECash flow / Net income0.81×Operating cash flow ÷ net incomeNet cash change−$85.60 MEnding cash − beginning cash
Chart details

WEST PHARMACEUTICAL SERVICES, INC. cash flow reconciliation, Apr 1, 2026 through Jun 30, 2026

Cash flows for Apr 1, 2026 through Jun 30, 2026. Cash basis: Cash, cash equivalents, and restricted cash. Beginning cash: Mar 31, 2026. Ending cash: Jun 30, 2026. Beginning and ending cash are dated balances. Positive cash flows add cash; negative cash flows reduce it.

Beginning cash on Mar 31, 2026
521,400,000 US dollars. Beginning cash: Cash, cash equivalents, and restricted cash
Operating activities
124,000,000 US dollars. Net cash provided.
Net income
154,000,000 US dollars
Depreciation
45,700,000 US dollars
Amortization
500,000 US dollars
Stock-based compensation
10,900,000 US dollars
Asset impairments
3,900,000 US dollars
Non-cash restructuring charges
1,000,000 US dollars
Other non-cash items, net
negative 6,000,000 US dollars
Changes in assets and liabilities
negative 86,000,000 US dollars
Investing activities
negative 43,200,000 US dollars. Net cash used.
Capital expenditures
negative 43,200,000 US dollars
Financing activities
negative 164,800,000 US dollars. Net cash used.
Borrowings under revolving credit agreements
50,000,000 US dollars
Repayments under revolving credit agreements
negative 50,000,000 US dollars
Principal repayments on finance leases
negative 400,000 US dollars
Excise tax payments
negative 800,000 US dollars
Dividend payments
negative 15,700,000 US dollars
Proceeds from stock-based compensation awards
6,900,000 US dollars
Employee stock purchase plan contributions
1,900,000 US dollars
Shares purchased under share repurchase programs
negative 156,700,000 US dollars
Shares repurchased for employee tax withholdings
0 US dollars
Operating adjustment reconciliation
92,000,000 US dollars. Intermediate calculation joining the operating reconciliation branches. Its gross amount includes any portion of net income routed through this junction. It is not an additional cash source or use.
financing gross reconciliation
223,600,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
investing gross reconciliation
43,200,000 US dollars. Gross amount at the activity's junction before offsetting its receipts and deductions. It is not an additional cash source or use.
Exchange-rate effect
negative 1,600,000 US dollars
Ending cash on Jun 30, 2026
435,800,000 US dollars. Ending cash: Cash, cash equivalents, and restricted cash
Cash sources and uses
645,400,000 US dollars. Opening cash plus net sources, equal to net uses plus ending cash.
Net cash change
negative 85,600,000 US dollars. Ending cash minus beginning cash.
Cash flow / Net income
0.81×. Operating cash flow divided by reconciliation net income for the same period. Black from 0.90× through 1.10×; green above 1.10×; red below 0.90×. Color uses the unrounded ratio.
Operating cash flow
124,000,000 US dollars. Operating cash flow used in the free cash flow calculation.
Cash purchases of property, plant and equipment
43,200,000 US dollars. These cash purchases are already included in investing activities above.
Free cash flow
80,800,000 US dollars. A supplemental measure; finance-lease payments are excluded from this definition.

Chart connections

  • Beginning cash plus operating, investing and financing cash flows plus the exchange-rate effect equals ending cash. Negative amounts reduce cash.
  • Financing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Investing contributions meet at a reconciliation junction before connecting to the net cash total.
  • Operating reconciliation adjustments are not all independent cash receipts.
  • Net income exceeds operating cash. The diagram allocates $124.00M of net income directly to operating cash and $30.00M to the adjustment junction, where it combines with other additions to reconcile deductions. This is an accounting presentation, not a tracing of cash receipts.
  • Each activity has one net cash bar connected to the shared cash pool. Positive activity totals enter the pool; negative activity totals leave the pool to fund that activity's net payments. The central pool does not assign a particular funding source to a particular payment.
  • The intermediate calculation bars include both sides of the displayed activity breakdowns; they are not additional cash flows.
  • Operating cash flow minus cash purchases of property, plant and equipment equals free cash flow: 124,000,000 US dollars minus 43,200,000 US dollars equals 80,800,000 US dollars.
WEST PHARMACEUTICAL SERVICES, INC. (WST) FY2026 Q2 Statement of Cash Flows Sankey chart
Free to share unchanged, with credit to Plicit.ai · CC BY-NC-ND 4.0Download PNG

Newsletter

Get the teardowns by email

Subscribe if you want the public-company teardowns in your inbox when they're released.

Product waitlist

Health Check and Teardown for your own company

A health check uncovers insights of your private books, not a public ticker. Join this list to get notified as soon as we go-live!